Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.56 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.56 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.56 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.56 |
| ▸ | DUT | P33316 | 3/20 | 0.52 |
| ▸ | TK1 | P04183 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8182746 | 1.00 | SLC28A1 (0.56) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL11222942 | 1.00 | SLC28A1 (0.56) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL11222933 | 1.00 | SLC28A1 (0.56) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL11222936 | 1.00 | SLC28A1 (0.56) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL18503452 | 0.91 | SLC28A1 (0.53) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL25386962 | 0.88 | SLC28A1 (0.50) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| Deoxyuridine SCHEMBL114598 | 0.86 | DUT (0.64) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| Deoxyuridine SCHEMBL4847460 | 0.86 | DUT (0.64) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| Deoxyuridine SCHEMBL889540 | 0.86 | DUT (0.64) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| Deoxyuridine SCHEMBL9219261 | 0.86 | DUT (0.64) | SLC28A1SLC28A2SLC29A1SLC28A3DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6121431-A | VIRICIDES AGAINST HUMAN IMMUNODEFICIENCY VIRUS AND HEPATITIS B VIRUS | MEDIVIR AB (SE) | 2000-09-19 | — | — | US | disclosed |
| US-5952500-A | VIRICIDES CAN BE USED IN THERAPEUTIC AND PROPHYLACTIC TREATMENT OF THE ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS), INFECTIONS OF HUMAN IMMUNE DEFICIENCY VIRUSES, HEPATITIS B VIRUS, HERPES VIRUSES AND CANCER | MEDIVIR AB (SE) | 1999-09-14 | — | — | US | disclosed |
| US-5747473-A | L-nucleoside analogues and pharmaceutical compositions | MEDIVIR AB (SE) | 1998-05-05 | — | — | US | disclosed |
| US-5473063-A | Reacting 2,3-epoxy-butanediol/1,4-/(having protected hydroxyl groups) with an alpha allylic nucleophile yields 2-hydroxy-3-allyl-1,4-butanediol, then oxidatively cleaving the double bond, cyclization, halogenation, acetylation or oxyalkylation | MEDIVIR AB (SE) | 1995-12-05 | — | — | US | disclosed |
| EP-0309560-B1 | NUCLEOSIDES AND NUCLEOSIDE ANALOGUES, PHARMACEUTICAL COMPOSITION AND PROCESSES FOR THE PREPARATION OF THE COMPOUNDS | MEDIVIR AB (SE) | 1994-12-21 | — | — | EP | disclosed |
| WO-1992006102-A1 | NUCLEOSIDE DERIVATIVES | MEDIVIR AB (SE) | 1992-04-16 | — | — | WO | disclosed |